脑源性FGF20靶标脑血管对创伤性脑损伤的保护和修复作用及其机制研究
批准号:
81971180
项目类别:
面上项目
资助金额:
55.0 万元
负责人:
林丽
依托单位:
学科分类:
神经损伤、修复与再生
结题年份:
2023
批准年份:
2019
项目状态:
已结题
项目参与者:
林丽
中文摘要
创伤性脑损伤(TBI)治疗的核心是保护继发性脑损伤的病理进展,明确以脑血管为靶标的继发性脑损伤病理机制,并寻找新的神经血管保护药物是TBI的一个重要研究方向。FGF20是一种脑源性的神经营养因子,有着独特的神经生物功能,尤其是对神经血管单元具有强大的保护和修复作用。我们前期动物实验发现,重组人FGF20可以明显减轻TBI小鼠血脑屏障的破坏,促进脑血管的再生和血管源性神经营养因子的分泌、修复神经元和少突胶质前体细胞的增殖。本项目拟从体内和体外水平上验证我们的理论假设:FGF20在TBI急性期能减轻血脑屏障的破坏,进而降低脑水肿、小胶质细胞激活和促炎因子的分泌,减少继发性神经元死亡;在亚急性期和修复期能促进脑血管再生、提高血管源性生长因子的分泌,从而促进内源性神经再生、白质重塑和长期神经功能的康复。本项目将深入阐明FGF20靶标脑血管治疗TBI的作用及机制,为TBI的治疗提供新的思路和方法。
英文摘要
The central purpose of traumatic brain injury (TBI) therapy is to protect against the pathological progress of secondary brain injury. To clarify the pathological mechanism of secondary brain injury centered on cerebrovascular target and to seek for new neurovascular protective compounds has become an important direction of TBI research. FGF20 is a kind of brain-derived neurotrophic factor with unique neurobiological function. Especially, it has powerful neurovascular unit protection and brain tissue repair effect. In our previous animal experiments, we found that recombinant human FGF20 could significantly reduce blood-brain barrier disruption, promote angiogenesis of cerebral vessels and vascular-derived neurotrophic factor secretion, repair and remodeling of white matter, and enhance long-term neurological function recovery of TBI in mice. By using in vivo TBI model and in vitro cell cultures, this project is aimed to test our hypothesis that in the acute phase of TBI, FGF20 can reduce blood-brain barrier damage, and consequently reduce brain edema, microglia/macrophage activation and pro-inflammatory factors secretion, and as well reduce the secondary neuronal death; in subacute/recovery phase of TBI, FGF20 may promote vascular-derived neurotrophic factor secretion, cerebrovascular angiogenesis, and neurogenesis, and improve white matter remodeling and long-term neurological function recovery. This project would help in understanding cerebrovascular targeting effects and underlying mechanisms, it would also provide new insight into cerebrovascular target strategy and new TBI therapy approach development.
期刊论文列表
专著列表
科研奖励列表
会议论文列表
专利列表
登录
查看更多内容
DOI:
10.3389/fphar.2020.590669
发表时间:
2020
期刊:
Frontiers in pharmacology
影响因子:
5.6
作者:
[Chen J, Wang X, Hu J, Du J, Dordoe C, Zhou Q, Huang W, Guo R, Han F, Guo K, Ye S, Lin L, Li X]
通讯作者:
Li X
Roles of Fibroblast Growth Factors and Their Therapeutic Potential in Treatment of Ischemic Stroke.
成纤维细胞生长因子在缺血性中风治疗中的作用及其治疗潜力
DOI:
10.3389/fphar.2021.671131
发表时间:
2021
期刊:
Frontiers in pharmacology
影响因子:
5.6
作者:
[Dordoe C, Chen K, Huang W, Chen J, Hu J, Wang X, Lin L]
通讯作者:
Lin L
DOI:
10.1007/s10571-022-01193-9
发表时间:
2023-01
期刊:
Cellular and molecular neurobiology
影响因子:
4
作者:
[]
通讯作者:
DOI:
10.1016/j.cytogfr.2023.07.005
发表时间:
2023
期刊:
Cytokine Growth Factor Reviews
影响因子:
作者:
[Confidence Dordoe, Wenting Huang, Canol Bwalya, Xue Wang, Bixin Shen, Hao Wang, Jing Wang, Shasha Ye, Peng Wang, Bao Xiaoyan, Xiaokun Li, Li Lin]
通讯作者:
Li Lin
DOI:
10.1016/j.neuropharm.2022.109064
发表时间:
2022-04-26
期刊:
NEUROPHARMACOLOGY
影响因子:
4.7
作者:
[Dordoe, Confidence, Wang, Xue, Li, Xianfeng]
通讯作者:
Li, Xianfeng
共 6 条
眼病精准诊疗技术与创新药物、装备研发及应用-治疗外伤性视神经病变的高负载bFGF水凝胶创新药物的研发
-
批准号:2025C02152
-
项目类别:省市级项目
-
资助金额:0.0万元
-
批准年份:2025
-
负责人:林丽
-
依托单位:
细胞外囊泡靶向递送aFGF对2型糖尿病合并缺血性脑卒中神经血管再生及功能修复研究
-
批准号:82372149
-
项目类别:面上项目
-
资助金额:49万元
-
批准年份:2023
-
负责人:林丽
-
依托单位:
FGF21调控FGFR1/GR通路对抑郁症的治疗作用及其机制研究
-
批准号:LZ23H310001
-
项目类别:省市级项目
-
资助金额:0.0万元
-
批准年份:2023
-
负责人:林丽
-
依托单位:
可注射温敏型肝素泊洛沙姆-FGF20水凝胶对缺血性脑卒中神经血管单元修复与再生作用研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:55万元
-
批准年份:2021
-
负责人:林丽
-
依托单位:
FGF21调控小胶质细胞介导的神经免疫炎症促进2型糖尿病缺血性脑卒中后神经功能的修复
-
批准号:81771284
-
项目类别:面上项目
-
资助金额:54.0万元
-
批准年份:2017
-
负责人:林丽
-
依托单位:
国内基金
海外基金